# In silico interaction analysis of selected natural compounds with bacteriophage-encoded hyaluronate lyase from Streptococcus pyogenes

**Authors:** Samia S. Alkhalil

PMC · DOI: 10.3389/fmed.2026.1709023 · Frontiers in Medicine · 2026-02-16

## TL;DR

This study uses computer modeling to find natural compounds that can inhibit a key virulence factor in Streptococcus pyogenes, offering a potential alternative to antibiotics.

## Contribution

The paper introduces a novel in silico approach to identify natural HylP2 inhibitors with favorable pharmacokinetic properties.

## Key findings

- Violacein, sulfangolid C, chlorotonil A, xiamycin, and kulkenon showed strong binding to HylP2.
- MD simulations confirmed stable interactions of violacein, xiamycin, and kulkenon with key catalytic residues.
- The compounds comply with Lipinski’s Rule of Five and show favorable ADMET profiles.

## Abstract

The rising antibiotic resistance of Streptococcus pyogenes necessitates alternative anti-virulence strategies. Bacteriophage-encoded hyaluronate lyase (HylP2), a key virulence factor that promotes bacterial dissemination by degrading host extracellular matrix components, represents an attractive therapeutic target.

In this study, an integrated in silico approach was employed to identify potential HylP2 inhibitors from a library of 118 bioactive natural compounds. Following protocol validation through redocking of ascorbic acid (RMSD = 1.897 Å), virtual screening, ADMET prediction, molecular dynamics (MD) simulations, and per-residue energy decomposition analyses were performed.

Violacein (−7.7 kcal/mol), sulfangolid C (−7.427 kcal/mol), chlorotonil A (−7.4 kcal/mol), xiamycin (−7.3 kcal/mol), and kulkenon (−7.1 kcal/ mol) were identified as the most potent binders. ADMET analysis confirmed that these leads possess favorable pharmacokinetic properties and compliance with Lipinski’s Rule of Five. Subsequent 100-ns molecular dynamics (MD) simulations and per-residue energy decomposition revealed that violacein, xiamycin, and kulkenon formed stable, compact complexes by “trapping” catalytic residues Arg279 and Tyr264.

These findings suggest that these natural product scaffolds are promising anti-virulence leads that may limit S. pyogenes tissue invasion while minimizing selective pressure for resistance development.

## Linked entities

- **Proteins:** hylP.2 (hyaluronidase N-terminal portion)
- **Chemicals:** Violacein (PubChem CID 11053), sulfangolid C (PubChem CID 86575985), chlorotonil A (PubChem CID 24742044), xiamycin (PubChem CID 38358410), kulkenon (PubChem CID 86576052), ascorbic acid (PubChem CID 9888239)
- **Species:** Streptococcus pyogenes (taxon 1314)

## Full-text entities

- **Genes:** ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}
- **Diseases:** scarlet fever (MESH:D012541), Infection (MESH:D007239), cytotoxicity (MESH:D064420), necrotizing fasciitis (MESH:D019115), respiratory toxicity (MESH:D012140), carcinogenic (MESH:D011230), eye irritation (MESH:D005128), streptococcal toxic shock syndrome (MESH:D012772), sepsis (MESH:D018805), infectious diseases (MESH:D003141), skin and throat infections (MESH:C538390), liver injury (MESH:D017093), liver damage (MESH:D056486)
- **Chemicals:** ergosterol (MESH:D004875), quercetin (MESH:D011794), Myxochelin A (MESH:C058735), aphidicolin (MESH:D016590), Phenoxan (MESH:C077638), pinocembrin (MESH:C016063), 3-chloro-9H-carbazole (MESH:C558654), anaephene B (MESH:C000718711), emodin (MESH:D004642), sabinene (MESH:C035127), 4-hydroxymethyl-quinoline (MESH:C550905), althiomycin (MESH:C010018), nannozinone B (MESH:C000599245), Cl- (MESH:D002713), Triton X-100 (MESH:D017830), citreorosein (MESH:C540595), chondroitin sulfates (MESH:D002809), NaCl (MESH:D012965), Sophorastilbene A (-), brefeldin A (MESH:D020126), 10-methoxydihydrofuscin (MESH:C479848), n-octanol (MESH:D020003), Na+ (MESH:D012964), penicillin (MESH:D010406), ergothioneine (MESH:D004880), 6-Pentyl-2H-pyran-2-one (MESH:C008798), glycosaminoglycan (MESH:D006025), kojic acid (MESH:C011890), ascorbic acid (MESH:D001205), sodium dodecyl sulfate (MESH:D012967), ergosterol peroxide (MESH:C036071), Hydrogen (MESH:D006859), melithiazol A (MESH:C401242), xiamycin (MESH:C556785), carolacton (MESH:C553423), dermatan sulfates (MESH:D003871), xanthone (MESH:C009689), Violacein (MESH:C063155), lysergic acid (MESH:D008237), HA (MESH:D006820), Baicalein (MESH:C006680), Chlorotonil A (MESH:C526339), hinnuliquinone (MESH:C494428), glutathione (MESH:D005978), thiangazole (MESH:C085039), cytosporin A (MESH:C099196), aureonitol (MESH:C533114), kaempferol (MESH:C006552), epothilon D (MESH:C114026), aurachin E (MESH:C568009), griseofulvin (MESH:D006118), water (MESH:D014867), cyclo(L-Phe-L-Pro) (MESH:C118540), apigenin (MESH:D047310), velutin (MESH:C577620), xantocillin (MESH:C493153), Aloin B (MESH:C006457), bikaverin (MESH:C000269)
- **Species:** Gastromermis sp. AS (species) [taxon 211381], Streptococcus sp. 'group A' (species) [taxon 36470], Homo sapiens (human, species) [taxon 9606], Streptococcus mutans (species) [taxon 1309], Streptococcus equi (species) [taxon 1336], Streptomyces sp. SA (species) [taxon 1288406], Streptococcus pyogenes (species) [taxon 1314], Bacteriophage sp. (species) [taxon 38018]
- **Mutations:** H4489A
- **Cell lines:** SF370.1 — Homo sapiens (Human), Niemann-Pick disease, type A, Finite cell line (CVCL_W058)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950598/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950598/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950598/full.md

---
Source: https://tomesphere.com/paper/PMC12950598